Payment overview · 2025
General Payments
$382.80
21 reported records · 11 companies
Healthcare provider profile · identity verified
Lore Beth Wootton, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · WEISER, ID · NPI 1649365404
Verified facts
What the public records show
CMS Open Payments records show Lore Beth Wootton, M.D. received $382.80 in general payments during 2025 across 21 reported records.
Novo Nordisk Inc accounted for 16.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $64.58 | 16.9% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $49.95 | 13.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $47.67 | 12.4% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $47.51 | 12.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $47.19 | 12.3% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $30.05 | 7.8% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.84 | 6.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.39 | 5.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.57 | 5.1% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $16.75 | 4.4% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $14.30 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $382.80 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $49.95 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $47.67 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $47.67 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $47.51 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $30.05 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.05 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $30.05 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $28.51 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $28.51 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $22.84 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $22.70 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.39 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.57 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.82 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.04 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $14.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 78 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
78 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
144 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 479 | 124 |
| Atorvastatin Calcium | Atorvastatin Calcium | 390 | 110 |
| Omeprazole | Omeprazole | 250 | 72 |
| Lisinopril | Lisinopril | 249 | 63 |
| Amlodipine Besylate | Amlodipine Besylate | 237 | 68 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 210 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 201 | 54 |
| Alprazolam | Alprazolam | 190 | 37 |
| Eliquis | Apixaban | 144 | 30 |
| Gabapentin | Gabapentin | 144 | 45 |
| Furosemide | Furosemide | 139 | 34 |
| Alendronate Sodium | Alendronate Sodium | 134 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 129 | 35 |
| Trazodone Hcl | Trazodone Hcl | 129 | 36 |
| Meloxicam | Meloxicam | 125 | 37 |
| Losartan Potassium | Losartan Potassium | 123 | 37 |
| Simvastatin | Simvastatin | 123 | 32 |
| Potassium Chloride | Potassium Chloride | 122 | 30 |
| Glimepiride | Glimepiride | 111 | 30 |
| Quetiapine Fumarate | Quetiapine Fumarate | 102 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 97 | 29 |
| Irbesartan | Irbesartan | 97 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 94 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 84 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 82 | 18 |
| Metformin Hcl | Metformin Hcl | 82 | 23 |
| Ozempic | Semaglutide | 78 | 14 |
| Farxiga | Dapagliflozin Propanediol | 73 | 15 |
| Metformin Hcl Er | Metformin Hcl | 71 | 21 |
| Ezetimibe | Ezetimibe | 68 | 16 |
| Sertraline Hcl | Sertraline Hcl | 66 | 14 |
| Tramadol Hcl | Tramadol Hcl | 66 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | 18 |
| Prednisone | Prednisone | 65 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 64 | 30 |
| Famotidine | Famotidine | 63 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 62 | 22 |
| Donepezil Hcl | Donepezil Hcl | 58 | 11 |
| Buspirone Hcl | Buspirone Hcl | 57 | 11 |
| Estradiol | Estradiol | 57 | 19 |
| Xarelto | Rivaroxaban | 52 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 51 | 12 |
| Baclofen | Baclofen | 50 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 50 | 13 |
| Spironolactone | Spironolactone | 49 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 49 | 18 |
| Allopurinol | Allopurinol | 47 | 14 |
| Cephalexin | Cephalexin | 43 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 41 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 16 |
| Valsartan | Valsartan | 40 | 15 |
| Mirtazapine | Mirtazapine | 39 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | suppressed |
| Celecoxib | Celecoxib | 34 | suppressed |
| Clonazepam | Clonazepam | 33 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 33 | suppressed |
| Lovastatin | Lovastatin | 33 | suppressed |
| Azithromycin | Azithromycin | 32 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 32 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | suppressed |
| Cefdinir | Cefdinir | 29 | 27 |
| Promethazine Hcl | Promethazine Hcl | 29 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Carvedilol | Carvedilol | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 24 |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Lactulose | Lactulose | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Fluconazole | Fluconazole | 24 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 21 |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Lorazepam | Lorazepam | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 16 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Carisoprodol | Carisoprodol | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 13 |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | 11 |
| Hydromorphone Hcl | Hydromorphone Hcl | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Dexamethasone | Dexamethasone | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Mesalamine | Mesalamine | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $382.80 · 21 records | Novo Nordisk Inc | CAPLYTA, ENTRESTO, EVENITY, FREESTYLE LIBRE 3, General - Pain Management, LEQVIO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, Wegovy, YUPELRI, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error